← Eichor
Condition: Glomerulosclerosis Focal Segmental Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Glomerulosclerosis Focal Segmental

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis
Phase N/A · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT07010250NEPTUNE Match Study
NA · 16 location(s) · University of Michigan · NCT04571658ARREST-NEPHROSIS - Austrian Resistant Nephrotic Syndrome Treatment Response Registry and Biobank
Phase N/A · 1 location(s) · Christoph Aufricht · NCT06162546Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.
Phase N/A · 1 location(s) · University of Michigan · NCT05505500AMPK-activation by Metformin in FSGS: AMP-FSGS
Phase 1/Phase 2 · 2 location(s) · Yale University · NCT06090227A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
Phase 2 · 23 location(s) · Akebia Therapeutics · NCT07268638The FOrMe Registry (The German Focal Segmental Glomerulosclerosis and Minimal Change Disease Registry)
Phase N/A · 12 location(s) · Prof. Dr. Paul Brinkkoetter · NCT03949972Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
Phase 2 · 47 location(s) · Travere Therapeutics, Inc. · NCT05003986Proteinuria in Pre and Post Transplant
Phase N/A · 1 location(s) · University of Miami · NCT01094327Raman Spectroscopy Diagnosis of Kidney Diseases
Phase N/A · 1 location(s) · Zunsong Wang · NCT06760845Study of WAL0921 in Patients With Glomerular Kidney Diseases
Phase 2 · 50 location(s) · Walden Biosciences · NCT06466135Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
NA · 12 location(s) · Kaneka Medical America LLC · NCT02235857INSIGHT (Insight Into Nephrotic Syndrome)
Phase N/A · 4 location(s) · The Hospital for Sick Children · NCT01605266An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomeruloscleros
Phase 2 · 1 location(s) · National Human Genome Research Institute (NHGRI) · NCT06664814Autoantibodies Against-nephrin in Idiopathic Nephrotic Syndrome
Phase N/A · 1 location(s) · Mario Negri Institute for Pharmacological Research · NCT06334692A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis
Phase 2/Phase 3 · 1 location(s) · Bio-Thera Solutions · NCT07499700Nephrotic Syndrome Study Network
Phase N/A · 44 location(s) · University of Michigan · NCT01209000A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects
Phase 1 · 1 location(s) · Hansoh BioMedical R&D Company · NCT05942625China Kidney Patient Trials Network
Phase N/A · 1 location(s) · George (Beijing) Clinical Research Co. Ltd. · NCT05036850Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System
NA · 10 location(s) · Kaneka Medical America LLC · NCT04065438A Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS)
NA · 2 location(s) · Northwell Health · NCT05583942A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosc
Phase 3 · 296 location(s) · Boehringer Ingelheim · NCT07220083A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
Phase 3 · 220 location(s) · Dimerix Bioscience Pty Ltd · NCT05183646Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinur
Phase 2 · 2 location(s) · Everest Medicines (China) Co.,Ltd. · NCT07614477SLIT ABS: Study on Patients With Autoimmune Podocytopathy
NA · 14 location(s) · Meyer Children's Hospital IRCCS · NCT07516964A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Ye
Phase 2 · 71 location(s) · Sanofi · NCT06500702INS, B Cells and Microbiota
Phase N/A · 2 location(s) · Nantes University Hospital · NCT04924712National Registry of Rare Kidney Diseases
Phase N/A · 1 location(s) · UK Kidney Association · NCT06065852taVNS for FRNS in Children
NA · 2 location(s) · Northwell Health · NCT05588063KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis
Phase N/A · 6 location(s) · Seoul National University Hospital · NCT03929887
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.